Cyclin-dependent kinase (CDK) pathways are often dysregulated in AML. CDKs control cell-cycle progression and gene transcription. Inhibiting CDKs can lead to downregulation of cell survival genes which are regulated by MCL-1, MYC,and cyclin D1. CDK9 is one target of therapeutic agents in AML. CDK inhibitors such as alvocidib, dinaciclib, and TG02 are in clinical development.